Faeth Therapeutics stock
FTHNASDAQFaeth Therapeutics, Inc., HealthcareISIN US81728A2078
35Score 35 out of 100, Weak
Price and trend
41 / 100
Price history
+39% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 47% below it.
Since October 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 33).
The price is 67% below its 52-week high. Largest decline in 6 years: 99% (February 2021 to April 2025).
Chart figures for advanced users
- SMA 50$26.22
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.42
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)33
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$7.89
- The lowest closing price of the last twelve months.
- Resistance$40.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Faeth Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $344.15M, is number 281 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 35 out of 100 (Weak): rank 635 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $21.18M, financial debt $1.51M.Stability 54
Weaknesses
- Volatile share priceVolatility 223% a year over the last 12 months.Stability 54
- Loss-makingLoss of $21.09M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$20.47M over the last 12 months.Fundamentals 17
The score is held back by fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 0.1). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 29 Mar 2027in 137 days
- Last reported
- 3 Nov 2026EPS reported −$0.79 (expected −$0.78)in line with expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 6.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$14.70+2.4%
- Revenue
- $0
- Earnings per share
- −$3.48−6.1%
- Revenue
- $0
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
2 insiders bought on the open market in the last 6 months, $1.19M in total. One insider sold, $500,543 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Stephenson Brian CPurchase
1 Jul 2026, Chief Financial Officer
- Shares
- 5,000
- Price
- $23.50
- Value
- $117,492
- Stephenson Brian CPurchase
30 Jun 2026, Chief Financial Officer
- Shares
- 7,803
- Price
- $24.25
- Value
- $189,240
- Stephenson Brian CPurchase
29 Jun 2026, Chief Financial Officer
- Shares
- 831
- Price
- $23.34
- Value
- $19,396
Show 6 more
- Stephenson Brian CPurchase
26 Jun 2026, Chief Financial Officer
- Shares
- 6,250
- Price
- $24.95
- Value
- $155,908
- Stephenson Brian CPurchase
24 Jun 2026, Chief Financial Officer
- Shares
- 9,391
- Price
- $26.13
- Value
- $245,360
- Stephenson Brian CPurchase
23 Jun 2026, Chief Financial Officer
- Shares
- 9,230
- Price
- $24.36
- Value
- $224,806
- Stephenson Brian CPurchase
22 Jun 2026, Chief Financial Officer
- Shares
- 8,183
- Price
- $22.13
- Value
- $181,115
- Parikh Anand KiranPurchase
22 Jun 2026, President and CEO
- Shares
- 2,806
- Price
- $19.76
- Value
- $55,447
- Peyer James, Cambrian BioPharma IncSale
1 Jun 2026, Major holder
- Shares
- 25,000
- Price
- $20.02
- Value
- $500,543
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Faeth Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 35
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Eikon TherapeuticsEIKN $361.1M35
- Opus GeneticsIRD $358.57M43
- Century TherapeuticsIPSC $358.05M37
- AgomAb TherapeuticsAGMB $344.24M30
- Atea PharmaceuticalsAVIR $338.46M35
- Enanta PharmaceuticalsENTA $337.85M28
- Autolus TherapeuticsAUTL $330.04M31
- OcugenOCGN $325.87M36
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.